

NPPA order may not impact much: Reddy's

PRESS TRUST OF INDIA

Hyderabad

THE recent national pharmaceutical pricing authority (NPPA) order bringing in some more medicines under control may not have much impact on city-based drug maker Dr Reddy's Laboratories in terms of product pricing, according to a senior company official.

The company is assessing the impact and in touch with legal professionals seeking advice, the official said.

"This (the NPPA's order) has come a little bit out of blue. We are trying to see whether it needs any action. For us, it will be less material. The exposure to those products is lower and our work is in progress from impact assessment per-

spective. We have not been hit in a significant manner. We are still talking to the lawyers what to do," the official said.

In a move that is likely to bring down prices of some of the key medicines, drug pricing regulator NPPA has fixed the price of 108 non-scheduled formulation packs of 50 anti-diabetes and cardiac medicines.

The national pharma-

ceutical pricing authority (NPPA) has fixed the prices of anti-diabetic & cardiovascular in respect of 108 non-scheduled formulation packs under Paragraph 19 of DPCO, 2013, NPPA said in a notification.

The drugs that will become cheaper would include atorvastatin, glimepiride, glimepiride, heparin and metolazone among others.

Pricing.